Floatz logo

Proagio

Advanced Pancreatic Cancer

ProDa BioTech, LLCPhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Advanced Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
S-1
Liu Xiufeng
Phase 4BB
Docetaxel
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3BB
Metformin
State University of New York - Downstate Medical Center
Phase 2BB
Famitinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3B
Fluzoparib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3B

View all 46 →

Same molecule, other indications

Proagio is also rated in:

Solid Tumor MalignanciesDormant
CC
Indicative ·
42 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →